The legal status of CBD flower in the EU: How it’s actually sold

Key takeaways

• CBD flower is not governed by Novel Food — that regime applies to ingestible foods, not to raw flower.
• Flower is instead governed by national industrial-hemp and controlled-substance law, which varies sharply by country.
• The EU principle underpinning much of this is Kanavape: CBD lawfully produced in one member state generally cannot be subject to a blanket ban in another without a genuine, evidenced public-health justification.
• The “not for human consumption” framing exists because most national frameworks legalise low-THC hemp for industrial use but do not explicitly authorise selling flower for people to consume.
• Country positions diverge widely and are shifting — France permits flower sales, Italy has tried to restrict them, others are mid-debate.

Why CBD flower sits in a different legal category

The starting point is a distinction many resellers miss. Ingestible CBD — oils, capsules, edibles — is treated as food and runs into the Novel Food regime. Raw flower is not a food in that sense; you are selling plant material, not a food ingredient. So flower falls outside Novel Food and is instead governed by each country’s rules on industrial hemp and on controlled substances.

Underpinning the whole area is a single landmark EU ruling. In the Kanavape case (Court of Justice of the EU, C-663/18, November 2020), the Court held that CBD is not a narcotic, that it falls within the EU’s free-movement-of-goods provisions, and that a member state cannot impose a blanket ban on CBD lawfully produced in another member state unless it can show a genuine, scientifically substantiated risk to public health. Notably, the CBD in that case had been produced in the Czech Republic from the whole plant, including flowers, and imported into France. That free-movement principle is the legal backbone that resellers and producers repeatedly invoke when a national government tries to ban flower outright.

The “not for human consumption” framing explained

If you have bought wholesale flower, you have seen it labelled “not for human consumption,” or sold as a collector’s or aromatic item. It is worth understanding precisely what that framing is doing — and what it is not.

Most national frameworks legalise the cultivation and industrial processing of low-THC hemp and exempt the raw harvested plant from the definition of a narcotic. What they typically do not do is explicitly authorise the retail sale of flower for human consumption — for smoking or eating. The retail flower market grew up in the gap this left open. By positioning flower as not intended for consumption, sellers keep the product within the industrial-hemp framework rather than triggering food law (Novel Food), tobacco law, or narcotics law.

Two honest caveats belong here. First, this is a positioning grounded in how the law is written, not a universal shield: authorities and courts in some markets look at the intended use of a product, and the robustness of the framing varies. Second, it is precisely the question now being litigated in several countries. Treat the label as a real part of compliant positioning, not as a guarantee that resolves every market.

Country variation: where and how flower is sold

This is the part that cannot be generalised — a position in one country tells you nothing reliable about its neighbour. A snapshot of the spread as of mid-2026:

• France — Flower and leaves may be sold. After the Kanavape ruling, a 2021 decree still banned raw flower sales to consumers, but the Conseil d’État (decision n°444887, December 2022) struck that ban down as disproportionate. Products must come from approved varieties and stay within the THC limit.
• Czech Republic — Operates one of the most permissive frameworks, having raised its industrial-hemp THC ceiling to 1% and brought low-THC cannabis into a new licensed “psychomodulatory substances” regime. Note this is a domestic system with its own licensing and retail rules.
• Switzerland (non-EU) — Flower up to 1% THC is legal and openly sold, making it the region’s most permissive market — though Swiss-legal flower can exceed EU destination limits at the border.
• Italy — Contested. A 2025 decree sought to restrict hemp flower and resin, but the measure is heavily litigated and has been referred to the EU Court of Justice. The position is unstable; take current advice before relying on it.
• Germany — Cultivation follows the EU standard; flower from EU-catalogue varieties within the THC limit can be imported, but flower intended for smoking sits in a more fraught space, and a “no misuse for intoxication” test applies.
• Austria — Flower-type products are tolerated more readily than ingestibles, but CBD is restricted as a food supplement, and products are frequently labelled as not for consumption.
• Greece — A live example of the tension: the government has moved to ban hemp flower retail sales, while its own statutory advisory body warned the measure conflicts with EU law and the broader European trend of permitting flower under conditions.
• United Kingdom (non-EU) — A 2023 Court of Appeal ruling indicated low-THC hemp flower should not automatically be treated as a narcotic, but the retail flower position remains unsettled and is separate from the EU framework.

The pattern across Europe is a tug-of-war: national governments periodically attempt restrictions, and the EU free-movement principle pulls the other way. Expect continued movement.

Labelling and positioning to stay compliant

Whatever your market, a few practices reduce risk:

1. Use the correct framing for the market. Where flower is sold on a “not for human consumption” basis, label it consistently and accurately; do not undercut that positioning with consumption-oriented marketing.
2. Make no health or therapeutic claims. This is the fastest way to convert a hemp-law question into a medicines-law problem.
3. Stay within the destination’s THC rule. Confirm compliance against the market where the product is sold — see THC limits across Europe.
4. Keep a batch COA. Documentation of variety, origin and cannabinoid content is your evidence base — see reading a Certificate of Analysis.
5. Match product to market before you stock. Grades and formats sell differently and carry different rules; our guides to flower quality grades and flower, resin and extracts help with assortment.

Working with Highness. Flower rules differ market by market and change quickly. When you speak to a Highness sales agent, you can talk through what fits the country you sell into before committing to stock. Contact the Highness sales network for a commercial conversation.

Frequently asked questions

Is CBD flower legal in Europe?
It depends entirely on the country. Some markets permit flower sales (France, the Czech Republic, Switzerland), others restrict or are contesting them (Italy, Greece). There is no single EU-wide answer, and the picture is shifting.

Why is CBD flower sold as “not for human consumption”?
Because most national frameworks legalise low-THC hemp for industrial use but do not explicitly authorise selling flower to be consumed. The framing keeps the product within hemp law rather than triggering food, tobacco or narcotics rules. Its robustness varies by market.

Does Novel Food apply to CBD flower?
No. Novel Food governs ingestible foods. Raw flower falls under national industrial-hemp and controlled-substance rules instead.

What is the Kanavape ruling and why does it matter for flower?
It is the 2020 EU Court of Justice decision establishing that CBD is not a narcotic and that member states cannot impose blanket bans on CBD lawfully produced elsewhere in the EU without a genuine public-health justification. It is the principle most often used to challenge national flower bans.

Can I sell the same flower across different EU countries?
Not safely without checking each market. Destination rules govern, the legal status of flower varies widely, and some markets restrict it. Verify each country and take advice.

Sources

This overview draws on, among others: the Court of Justice of the EU, Kanavape (C-663/18, 2020); France’s décret of 30 December 2021 and Conseil d’État decision n°444887 (2022); Italy’s D.L. 48/2025 / Law 80/2025 and the subsequent CJEU referral; Czech industrial-hemp and psychomodulatory-substances legislation (2024–2025); Greek legislative proposals and the opinion of the Greek Economic and Social Committee (2025–2026); Swiss CBD provisions; and UK case law. Positions reflect the situation as understood in mid-2026 and are subject to change.

About this guide: prepared for resellers and buyers handling CBD flower across European markets. Reviewed by Highness Distribution. This article is general business information and does not constitute legal advice; flower rules vary by country and change frequently, so always verify the current position in your own market and take professional advice where appropriate.